Back

Verastem Oncology to present RAMP 201 analyses at IGCS 2026

Verifying
  • Verastem Oncology announced presentations of new RAMP 201 analyses at IGCS 2026.
  • The analyses describe outcomes for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.
  • The presentation materials include molecular profiling and external control arm analyses.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.